← FDA DRUG APPROVALS

FDA ANDA · ANDA205833

MOXIFLOXACIN HYDROCHLORIDE

Sponsor: MYLAN LABS LTD

APPLICATION
ANDA205833
TYPE
ANDA
ORIGINAL APPROVAL
2017-05-05
LATEST ACTION
2023-05-19
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINERPrescription
MOXIFLOXACIN HYDROCHLORIDE 400MG/250ML (1.6MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2023-05-19Labeling · Supplement 9 · standardAP
2019-12-04Labeling · Supplement 8 · standardAP
2019-05-03Labeling · Supplement 5 · standardAP
2019-04-30Labeling · Supplement 6 · standardAP
2018-10-18Labeling · Supplement 3 · standardAP
2017-05-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →